Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company advancing targeted therapies for challenging cancers. This page provides investors and researchers with direct access to official announcements and verified updates about the company’s oncology programs.
Key resources include: Clinical trial progress for lead candidate DKN-01 (targeting DKK1), developments in FL-301 (Claudin18.2 program), partnership announcements, and financial disclosures. All content is sourced from authorized releases to ensure reliability.
Users benefit from: Timely updates on regulatory milestones, research collaborations, and pipeline advancements in gastrointestinal/gastroesophageal cancers. Content is organized chronologically for efficient tracking of material events.
Bookmark this page to monitor Leap Therapeutics’ progress in developing precision antibody therapies, with new updates added as official announcements become available.
Leap Therapeutics (Nasdaq:LPTX) presented promising clinical data from its Phase 2 trial of DKN-01 during the Society of Gynecologic Oncology 2021 Annual Meeting. The study showcased DKN-01's effectiveness as a monotherapy and in combination with paclitaxel for patients with advanced gynecological cancers. Key findings revealed a complete response lasting over 2.5 years and improved outcomes for patients with DKK1-high tumors. Enhanced efficacy was noted in endometrioid histology patients. Leap is encouraged to further explore DKN-01, highlighting its tolerability and potential for improved survival rates.
Leap Therapeutics (Nasdaq:LPTX) reported its financial results for 2020, revealing a net loss of $27.5 million, down from $32.9 million in 2019, primarily due to reduced R&D expenses. The company secured a $51.75 million public offering and signed a licensing agreement with BeiGene for DKN-01 in key Asia-Pacific regions. Key advancements include positive outcomes in EGC cancer for DKN-01 and receiving both Orphan Drug and Fast Track Designations from the FDA. Cash and equivalents stood at $52.1 million as of December 31, 2020, signaling a stable financial position for ongoing projects.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at two upcoming virtual investor conferences. The first is the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 at 10 a.m. Eastern Time. The second is the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, with a presentation available at 7:00 a.m. Eastern Time on March 9. Leap focuses on developing targeted and immuno-oncology therapeutics, with its leading candidate, DKN-01, in clinical trials for various cancers.
Leap Therapeutics (Nasdaq:LPTX) announced a corporate overview presentation at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. Douglas E. Onsi, the company’s President and CEO, will present on January 11 at 6:00 a.m. Eastern Time. The presentation can be accessed on the company’s Investors page, with a replay available for a limited time. Leap is known for its immuno-oncology therapeutics, including the clinical candidate DKN-01, targeting various cancers.
Leap Therapeutics (Nasdaq:LPTX) announced that President and CEO Douglas E. Onsi will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET. The presentation will be available via webcast on the company's Investors page. Leap focuses on developing targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in clinical trials for various cancers. The company has a strategic partnership with BeiGene for DKN-01's development in Asia, excluding Japan.
Leap Therapeutics (Nasdaq:LPTX) announced the publication of preclinical results regarding DKN-01 in Molecular Cancer Research. DKN-01, a monoclonal antibody blocking the DKK1 protein, showed positive effects in mouse cancer models including tumor growth inhibition. The studies indicated that DKN-01 can activate NK cells and reduce metastases, suggesting its potential effectiveness in combination with PD-1 inhibitors. Leap has also initiated trials combining DKN-01 with BeiGene's tislelizumab for patients with high DKK1 levels in gastroesophageal cancers.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that CEO Douglas E. Onsi will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recording of the chat is accessible on the company’s investors page, with a replay available for 90 days. Leap focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate, currently in clinical trials for various cancers. The company collaborates with BeiGene for DKN-01's development in Asia, Australia, and New Zealand.
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its Q3 2020 financial results, showing a net loss of $7.1 million, down from $7.9 million in Q3 2019. Key highlights include the first patient dosed in a Phase 2a study of DKN-01 in combination with BeiGene's tislelizumab for metastatic gastric cancer. The FDA granted Fast Track designation to DKN-01 for high DKK1 expression G/GEJ cancer. The company ended the quarter with $58 million in cash and marketable securities, highlighting effective cost management with R&D expenses at $5.4 million, down from $5.8 million year-over-year.
Leap Therapeutics (Nasdaq:LPTX) announced that its President and CEO, Douglas E. Onsi, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference from November 16-18, 2020. The presentation is scheduled for November 16 at 9:20 a.m. ET and will be available via live webcast on the company's Investors page. Leap is focused on developing targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in clinical trials for various cancers. Further details on Leap can be found on their official website.
Leap Therapeutics (Nasdaq:LPTX) presented clinical data from its Phase 2 trial of DKN-01 for recurrent epithelial endometrial cancers at the AACR Virtual Conference on November 9-10, 2020. DKN-01, a monoclonal antibody targeting Dickkopf-1 (DKK1), showed efficacy in biomarker-selected patients, particularly those with Wnt signaling alterations. Key findings included a 10% overall response rate and improved outcomes in patients with Wnt activating mutations and high DKK1 expression. The study suggests DKN-01 offers a promising treatment option with a favorable safety profile.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
